Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Open access

Abstract

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we show that blood platelets interact with lung cancer cells and that PD-L1 protein is transferred from tumor cells to platelets in a fibronectin 1, integrin α5β1 and GPIbα-dependent manner. Platelets from NSCLC patients are found to express PD-L1 and platelet PD-L1 possess the ability to inhibit CD4 and CD8 T-cells. An algorithm is developed to calculate the activation independent adjusted PD-L1 payload of platelets (pPD-L1 Adj.), which is found to be superior in predicting the response towards ICI as compared to standard histological PD-L1 quantification on tumor biopsies. Our data suggest that platelet PD-L1 reflects the collective tumor PD-L1 expression, plays important roles in tumor immune evasion and overcomes limitations of histological quantification of often heterogeneous intratumoral PD-L1 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-27303-7

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Direct platelet-tumor cell interactions result in PD-L1 expression on the platelet surface. a Representative immunofluorescence staining of PD-L1 (red)and the platelet marker CD41 (green) in four different NSCLC tumor cell lines (A549, NCI-H23, NCI-H460, NCI-H226) co-incubated with human platelets (n = 3 biological replicates). Scale bars 200 μm. b Immunofluorescence microscopy of NCI-H460 cells interacting with human platelets derived from a healthy donor (PD-L1: red, CD41: green) (n = 3). Scale bar left 20 µm, right 10 µm. c Quantitative analysis of the PD-L1+ platelets per field of view (FoV), analyzed by immunofluorescence microscopy (n = 9 FoV (small symbols) were analyzed out of a total of n = 3 independent experiments (large symbols)). Horizontal lines represent means. d Percentage of PD-L1+ tumor cells per FoV (n = 3). Data are mean ± SEM. e Correlation of % PD-L1+ platelets/FoV vs. % PD-L1 tumor cells/FoV (n = 3). Correlation was determined by simple linear regression analysis. f Flow cytometry gating strategy for the quantification of PD-L1+ tumor cells (upper) and platelets (lower) after co-incubation. g, h Surface expression of PD-L1 and CD62P on control platelets (PLT) and platelets after co-incubation with A549, NCI-H23, NCI-H226, NCI-H460 cells (n = 4). Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. i Phase-contrast image of A549 tumor cells after 41 min coculture with platelets (ratio 1:1000). Overlaid migration tracks were color-coded based on their mean velocity. j Image sequence depicting tumor cell interaction and protrusion of a single platelet followed by detachment derived from zoom-in area indicated in (i). k Percentage of stable platelet–tumor cell contacts lasting from contact initiation until the end of the observation period (total observation time: 41 min). l Contact duration of platelet–tumor cell interactions. Data derived from the analysis of n = 75 platelets out of one independent experiment. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. m Scheme of vectors expressing PD-L1-GFP and FLAG-GFP used for transfection. n Immunofluorescence stainings of GFP of A549 cells transfected with FLAG-GFP or PD-L1-GFP (n = 3). Scale bar 50 µm. o Western blot analysis for PD-L1 in untreated and transfected A549 cells (n = 2). Vinculin was used as loading control. Presentation of full scan blots are provided in the Source data file. p, q Representative immunofluorescence microscopy of untreated, FLAG-GFP and PD-L1-GFP-transfected A549 cells interacting with platelets (n = 3). Tumor cells and platelets were stained for GFP (upper) and PD-L1 (lower). Scale bar 50 µm. r, s Flow-cytometry-based quantification of GFP (l) and PD-L1 (m) on platelet surfaces after co-incubation with untreated and transfected A549 cells (n = 3). t Expression of PD-L1 on platelets pre-treated with 100 µM cycloheximide after co-incubation with PD-L1-GFP-transfected A549 cells (n = 3). r–t Data are mean ± SEM. c, d, r–t Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. Source data are provided as a Source Data file.
Fig. 1 Direct platelet-tumor cell interactions result in PD-L1 expression on the platelet surface. a Representative immunofluorescence staining of PD-L1 (red)and the platelet marker CD41 (green) in four different NSCLC tumor cell lines (A549, NCI-H23, NCI-H460, NCI-H226) co-incubated with human platelets (n = 3 biological replicates). Scale bars 200 μm. b Immunofluorescence microscopy of NCI-H460 cells interacting with human platelets derived from a healthy donor (PD-L1: red, CD41: green) (n = 3). Scale bar left 20 µm, right 10 µm. c Quantitative analysis of the PD-L1+ platelets per field of view (FoV), analyzed by immunofluorescence microscopy (n = 9 FoV (small symbols) were analyzed out of a total of n = 3 independent experiments (large symbols)). Horizontal lines represent means. d Percentage of PD-L1+ tumor cells per FoV (n = 3). Data are mean ± SEM. e Correlation of % PD-L1+ platelets/FoV vs. % PD-L1 tumor cells/FoV (n = 3). Correlation was determined by simple linear regression analysis. f Flow cytometry gating strategy for the quantification of PD-L1+ tumor cells (upper) and platelets (lower) after co-incubation. g, h Surface expression of PD-L1 and CD62P on control platelets (PLT) and platelets after co-incubation with A549, NCI-H23, NCI-H226, NCI-H460 cells (n = 4). Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. i Phase-contrast image of A549 tumor cells after 41 min coculture with platelets (ratio 1:1000). Overlaid migration tracks were color-coded based on their mean velocity. j Image sequence depicting tumor cell interaction and protrusion of a single platelet followed by detachment derived from zoom-in area indicated in (i). k Percentage of stable platelet–tumor cell contacts lasting from contact initiation until the end of the observation period (total observation time: 41 min). l Contact duration of platelet–tumor cell interactions. Data derived from the analysis of n = 75 platelets out of one independent experiment. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. m Scheme of vectors expressing PD-L1-GFP and FLAG-GFP used for transfection. n Immunofluorescence stainings of GFP of A549 cells transfected with FLAG-GFP or PD-L1-GFP (n = 3). Scale bar 50 µm. o Western blot analysis for PD-L1 in untreated and transfected A549 cells (n = 2). Vinculin was used as loading control. Presentation of full scan blots are provided in the Source data file. p, q Representative immunofluorescence microscopy of untreated, FLAG-GFP and PD-L1-GFP-transfected A549 cells interacting with platelets (n = 3). Tumor cells and platelets were stained for GFP (upper) and PD-L1 (lower). Scale bar 50 µm. r, s Flow-cytometry-based quantification of GFP (l) and PD-L1 (m) on platelet surfaces after co-incubation with untreated and transfected A549 cells (n = 3). t Expression of PD-L1 on platelets pre-treated with 100 µM cycloheximide after co-incubation with PD-L1-GFP-transfected A549 cells (n = 3). r–t Data are mean ± SEM. c, d, r–t Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Fibronectin mediates platelet adhesion to tumor cells and facilitates PD-L1 protein transfer. a, b Expression of GFP (a) and PD-L1 (b) on platelet surfaces after co-incubation with six FLAG-GFP- and PD-L1-GFP--transfected NSCLC cell lines (A549, NCI-H322, NCI-H522, NCI-H23, HOP-62, HOP-92) (n = 3). c, d Ratio of GFP+ platelets/GFP+ tumor cells (c) and PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells (d) after co-incubation of platelets with transfected NSCLC cell lines (n = 3). e Heat map of relative fibrinogen (FBG), tissue factor (F3), fibronectin 1 (FN1) and von Willebrand factor (VWF) mRNA levels in all tested NSCLC cell lines (n = 3). f Relative mRNA level of FN1 in all tested NSCLC cell lines (n = 3). g Correlation ratio of PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells and relative FN1 mRNA level (n = 3). h Immunofluorescence images of platelet adhesion to NCI-H23 (upper left) and HOP-62 cells (upper right and lower) (fibronectin: green, platelets: red) (n = 3). Upper scale bar 100 µm, lower 20 µm. i Left, Quantification of adhesive platelets after co-incubation with NCI-H23 and HOP-62. Quantified as CD61+ area in %/FoV (n = 6 out of 3 independent experiments). Right, quantification of fibronectin covered area in %/FoV in NCI-H23 and HOP-62 cells (n = 6 out of 3 independent experiments). j Correlation of platelet and fibronectin covered area in %/FoV. k Immunofluorescence images of PD-L1 and fibronectin expression in HOP-62 cells (n = 2). Scale bar 20 µm. l Representative PLA with PD-L1 and fibronectin in HOP-62 cells. Scale bar left 20 µm, right 10 µm (n = 1). m Representative PLA with PD-L1 and fibronectin in NCI-H23 and HOP-62 cell (n = 3). Scale bar 10 µm. n PLA quantification of foci/cell in 119 NCI-H23 and 126 HOP-62 cells out of three biological replicates. o Western blot for PD-L1 and fibronectin in PD-L1-GFP-transfected HOP-62 cells after siRNA knockdown for fibronectin. Vinculin and α-Tubulin were used as loading controls (n = 2). Presentation of full scan blots are provided in the Source data file. p Expression of PD-L1 on platelets after co-incubation with PD-L1-GFP, PD-L1-GFP/siFN1, and PD-L1-GFP/siNC-transfected HOP-62 cells (n = 3). q Ratio PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells after co-incubation of platelets with PD-L1-GFP, PD-L1-GFP/siFN1, and PD-L1-GFP/siNC-transfected HOP-62 cells (n = 3). r Representative images of platelet adhesion to fibronectin-coated surface in the presence or absence of different platelet-blocking agents (n = 3). Scale bar 20 µm. s, t Quantitative analysis of the platelet adhesion assay as platelet covered area/FoV in % (s) and platelets/FoV (t) (n = 9 (small symbols) were analyzed out of three independent experiments (large symbols)). Horizontal lines represent mean. Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. u Quantification of PD-L1 on platelets after co-incubation with PD-L1-GFP-transfected HOP-62 cells with or without pre-treatment with platelet-blocking agents (n = 3). v Ratio PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells after co-incubation of platelets with PD-L1-GFP-transfected HOP-62 cells with or without pre-treatment with platelet-blocking agents (n = 3). a–d, f, p, q, u, v Data are mean ± SEM. Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. g, j Correlation was determined by simple linear regression analysis. I, n Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. Source data are provided as a Source Data file.
Fig. 2 Fibronectin mediates platelet adhesion to tumor cells and facilitates PD-L1 protein transfer. a, b Expression of GFP (a) and PD-L1 (b) on platelet surfaces after co-incubation with six FLAG-GFP- and PD-L1-GFP--transfected NSCLC cell lines (A549, NCI-H322, NCI-H522, NCI-H23, HOP-62, HOP-92) (n = 3). c, d Ratio of GFP+ platelets/GFP+ tumor cells (c) and PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells (d) after co-incubation of platelets with transfected NSCLC cell lines (n = 3). e Heat map of relative fibrinogen (FBG), tissue factor (F3), fibronectin 1 (FN1) and von Willebrand factor (VWF) mRNA levels in all tested NSCLC cell lines (n = 3). f Relative mRNA level of FN1 in all tested NSCLC cell lines (n = 3). g Correlation ratio of PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells and relative FN1 mRNA level (n = 3). h Immunofluorescence images of platelet adhesion to NCI-H23 (upper left) and HOP-62 cells (upper right and lower) (fibronectin: green, platelets: red) (n = 3). Upper scale bar 100 µm, lower 20 µm. i Left, Quantification of adhesive platelets after co-incubation with NCI-H23 and HOP-62. Quantified as CD61+ area in %/FoV (n = 6 out of 3 independent experiments). Right, quantification of fibronectin covered area in %/FoV in NCI-H23 and HOP-62 cells (n = 6 out of 3 independent experiments). j Correlation of platelet and fibronectin covered area in %/FoV. k Immunofluorescence images of PD-L1 and fibronectin expression in HOP-62 cells (n = 2). Scale bar 20 µm. l Representative PLA with PD-L1 and fibronectin in HOP-62 cells. Scale bar left 20 µm, right 10 µm (n = 1). m Representative PLA with PD-L1 and fibronectin in NCI-H23 and HOP-62 cell (n = 3). Scale bar 10 µm. n PLA quantification of foci/cell in 119 NCI-H23 and 126 HOP-62 cells out of three biological replicates. o Western blot for PD-L1 and fibronectin in PD-L1-GFP-transfected HOP-62 cells after siRNA knockdown for fibronectin. Vinculin and α-Tubulin were used as loading controls (n = 2). Presentation of full scan blots are provided in the Source data file. p Expression of PD-L1 on platelets after co-incubation with PD-L1-GFP, PD-L1-GFP/siFN1, and PD-L1-GFP/siNC-transfected HOP-62 cells (n = 3). q Ratio PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells after co-incubation of platelets with PD-L1-GFP, PD-L1-GFP/siFN1, and PD-L1-GFP/siNC-transfected HOP-62 cells (n = 3). r Representative images of platelet adhesion to fibronectin-coated surface in the presence or absence of different platelet-blocking agents (n = 3). Scale bar 20 µm. s, t Quantitative analysis of the platelet adhesion assay as platelet covered area/FoV in % (s) and platelets/FoV (t) (n = 9 (small symbols) were analyzed out of three independent experiments (large symbols)). Horizontal lines represent mean. Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. u Quantification of PD-L1 on platelets after co-incubation with PD-L1-GFP-transfected HOP-62 cells with or without pre-treatment with platelet-blocking agents (n = 3). v Ratio PD-L1-GFP+ platelets/PD-L1-GFP+ tumor cells after co-incubation of platelets with PD-L1-GFP-transfected HOP-62 cells with or without pre-treatment with platelet-blocking agents (n = 3). a–d, f, p, q, u, v Data are mean ± SEM. Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. g, j Correlation was determined by simple linear regression analysis. I, n Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Platelets from NSCLC patients show increased PD-L1 levels. a Left panel, left, Immunohistochemistry for CD61 in healthy human lung tissue (black arrow highlights CD61+ platelets). Scale bar 200 µm. Left panel, right, Representative micrograph of healthy lung tissue (H&E). Scale bar 500 µm. Right panel, Immunofluorescence microscopy for CD41+ (green), PD-L1- (red) platelets in healthy lung tissue (n = 3). Scale bar left 100 µm, right 10 µm. b Immunofluorescence staining for CD41 (green) and PD-L1 (red) on platelets in a PD-L1− NSCLC patient tumor sample (n = 3). Scale bar left 500 µm, center left 50 µm, center right and right 10 µm. c Upper, Representative micrographs of NSCLC adenocarcinoma (H&E) (n = 3). Scale bar left 250 µm, center 50 µm, right 500 µm. Lower, Immunofluorescence staining for CD41 (green) and PD-L1 (red) (n = 3). Scale bar left 500 µm, center left 50 µm, center right and right 10 µm. d, e Quantitative analysis of the platelets/FoV (d) and PD-L1+ platelets (%/FoV) (e) in healthy lung tissue, PD-L1+ and PD-L1- NSCLC patients (n = 9) (small symbols) were analyzed out of three independent experiments in three healthy donors and six NSCLC patients (large symbols). Horizontal line represent mean. f Percentage of PD-L1+ platelets in healthy donors (n = 64) and NSCLC patients (n = 128). Each dot represents a single donor. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. g Total amount of PD-L1 (pg/mL) in healthy donors (n = 21) and NSCLC patients (n = 64) analyzed by ELISA. Protein level were analyzed in 64 out of 128, randomly assigned patients of the NSCLC cohort. Data are mean ± SEM. h Total amount of PD-L1 (pg/mL) in PRP, platelet lysate, platelet releasate, and serum (n = 6). Data are mean ± SEM i Left, Representative PD-L1 immunofluorescence staining of platelets from a healthy donor (upper) and a NSCLC patient (lower). Platelets were counter stained with phalloidin. Right, Expression pattern of PD-L1 on a platelet derived from a NSCLC patient counter stained with phalloidin (upper) or CD41 (lower). Scale bar left 10 µm, right 2 µm (n = 1). j Platelets of a NSCLC patient, assessed by transmission electron microscopy. PD-L1 stained with post-embedding immunogold-labeling. PD-L1 gold particles densely accumulating on the platelet membrane (black dots). Upper scale bar 2 µm, lower 100 nm (n = 1). d, e, h Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. f, g Statistical significance was calculated by Mann–Whitney test. Source data are provided as a Source Data file.
Fig. 3 Platelets from NSCLC patients show increased PD-L1 levels. a Left panel, left, Immunohistochemistry for CD61 in healthy human lung tissue (black arrow highlights CD61+ platelets). Scale bar 200 µm. Left panel, right, Representative micrograph of healthy lung tissue (H&E). Scale bar 500 µm. Right panel, Immunofluorescence microscopy for CD41+ (green), PD-L1- (red) platelets in healthy lung tissue (n = 3). Scale bar left 100 µm, right 10 µm. b Immunofluorescence staining for CD41 (green) and PD-L1 (red) on platelets in a PD-L1− NSCLC patient tumor sample (n = 3). Scale bar left 500 µm, center left 50 µm, center right and right 10 µm. c Upper, Representative micrographs of NSCLC adenocarcinoma (H&E) (n = 3). Scale bar left 250 µm, center 50 µm, right 500 µm. Lower, Immunofluorescence staining for CD41 (green) and PD-L1 (red) (n = 3). Scale bar left 500 µm, center left 50 µm, center right and right 10 µm. d, e Quantitative analysis of the platelets/FoV (d) and PD-L1+ platelets (%/FoV) (e) in healthy lung tissue, PD-L1+ and PD-L1- NSCLC patients (n = 9) (small symbols) were analyzed out of three independent experiments in three healthy donors and six NSCLC patients (large symbols). Horizontal line represent mean. f Percentage of PD-L1+ platelets in healthy donors (n = 64) and NSCLC patients (n = 128). Each dot represents a single donor. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. g Total amount of PD-L1 (pg/mL) in healthy donors (n = 21) and NSCLC patients (n = 64) analyzed by ELISA. Protein level were analyzed in 64 out of 128, randomly assigned patients of the NSCLC cohort. Data are mean ± SEM. h Total amount of PD-L1 (pg/mL) in PRP, platelet lysate, platelet releasate, and serum (n = 6). Data are mean ± SEM i Left, Representative PD-L1 immunofluorescence staining of platelets from a healthy donor (upper) and a NSCLC patient (lower). Platelets were counter stained with phalloidin. Right, Expression pattern of PD-L1 on a platelet derived from a NSCLC patient counter stained with phalloidin (upper) or CD41 (lower). Scale bar left 10 µm, right 2 µm (n = 1). j Platelets of a NSCLC patient, assessed by transmission electron microscopy. PD-L1 stained with post-embedding immunogold-labeling. PD-L1 gold particles densely accumulating on the platelet membrane (black dots). Upper scale bar 2 µm, lower 100 nm (n = 1). d, e, h Statistical significance was calculated by one-way ANOVA and Tukey’s multiple comparisons test. f, g Statistical significance was calculated by Mann–Whitney test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 PD-L1 on platelets shows functional relevance via decreasing T-cell activity. a IFNγ ELISPOT assay of peptide-specific T-cells co-incubated with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). b Quantification of the IFNγ ELISPOT assays (n = 3). c Flow cytometry-based quantification of indicated cytokines and surface markers for peptide stimulated CD8+ T-cells co-incubated with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). d Representative FACS plots showing the gating strategy and the T-cell subpopulations after pre-sensitization, enrichment, and expansion. e Quantitative sub-phenotyping of NY-ESO-1 specific T cells using flow cytometry (n = 2). f Representative FACS plots displaying CD4+ TEM activity levels measured by INFγ expression after co-incubation with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). g Quantification of INFγ+CD4+ TEM (n = 3). h IFNy fold change in CD4+ TEM (n = 3). i Representative FACS plots displaying CD4+ TEM activity levels measured by TNFα expression after co-incubation with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). j Quantification of TNFα+CD4+ TEM (n = 3). k, TNFα fold change in CD4+ TEM (n = 3). b, c, g, h, j, k Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. Source data are provided as a Source Data file.
Fig. 4 PD-L1 on platelets shows functional relevance via decreasing T-cell activity. a IFNγ ELISPOT assay of peptide-specific T-cells co-incubated with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). b Quantification of the IFNγ ELISPOT assays (n = 3). c Flow cytometry-based quantification of indicated cytokines and surface markers for peptide stimulated CD8+ T-cells co-incubated with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). d Representative FACS plots showing the gating strategy and the T-cell subpopulations after pre-sensitization, enrichment, and expansion. e Quantitative sub-phenotyping of NY-ESO-1 specific T cells using flow cytometry (n = 2). f Representative FACS plots displaying CD4+ TEM activity levels measured by INFγ expression after co-incubation with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). g Quantification of INFγ+CD4+ TEM (n = 3). h IFNy fold change in CD4+ TEM (n = 3). i Representative FACS plots displaying CD4+ TEM activity levels measured by TNFα expression after co-incubation with PD-L1+ platelets with or without anti-PD-L1 mAb pre-treatment (n = 3). j Quantification of TNFα+CD4+ TEM (n = 3). k, TNFα fold change in CD4+ TEM (n = 3). b, c, g, h, j, k Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 pPD-L1 correlates with T cell infiltration in NSCLC. a, b Upper, Representative micrographs of NSCLC adenocarcinoma (H&E) (n = 11). Scale bar 500 µm. Lower, Immunofluorescence staining for T-cells (CD2: red, CD3: orange and PD-1: white) in the TME of a NSCLC patient presenting with low pPD-L1 (a) and high pPD-L1 (b). Each image is representative for at least two regions of interest (ROI) in each tumor sample. ROI were selected based on manual prestaining of DAPI. Scale bar 100 µm (n = 11). c–f Quantification of T cells per FoV (c), PD-1+ T cells per FoV (%) (d), infiltrating T cells per FoV (e) and PD-1+ infiltrating T cells per FoV (%) (f). pPD-L1 high vs. low was defined according to the median expression in this cohort. A total number of n = 22 ROIs (small symbols) were analyzed out of a total of n = 11 patients (large symbols). Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test (d–f) or two-tailed Mann–Whitney test (c). Source data are provided as a Source Data file.
Fig. 5 pPD-L1 correlates with T cell infiltration in NSCLC. a, b Upper, Representative micrographs of NSCLC adenocarcinoma (H&E) (n = 11). Scale bar 500 µm. Lower, Immunofluorescence staining for T-cells (CD2: red, CD3: orange and PD-1: white) in the TME of a NSCLC patient presenting with low pPD-L1 (a) and high pPD-L1 (b). Each image is representative for at least two regions of interest (ROI) in each tumor sample. ROI were selected based on manual prestaining of DAPI. Scale bar 100 µm (n = 11). c–f Quantification of T cells per FoV (c), PD-1+ T cells per FoV (%) (d), infiltrating T cells per FoV (e) and PD-1+ infiltrating T cells per FoV (%) (f). pPD-L1 high vs. low was defined according to the median expression in this cohort. A total number of n = 22 ROIs (small symbols) were analyzed out of a total of n = 11 patients (large symbols). Data are mean ± SEM. Statistical significance was calculated by two-tailed Student’s t test (d–f) or two-tailed Mann–Whitney test (c). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Platelets from NSCLC patients show increased PD-L1 protein levels upon activation. a Correlation between platelet-derived PD-L1 (pPD-L1) and platelet activation (CD62P expression) in 128 NSCLC patients. Each dot represents a single patient. b Platelets from a NSCLC patient assessed by transmission electron microscopy. PD-L1 stained with post-embedding immunogold-labeling. Upper and lower right, PD-L1 gold particles densely accumulate in α-granules. Scale bar left 1 µm, right 100 nm (n = 1). c, d Changes in CD62P (c) and the pPD-L1 (d) levels upon platelet stimulation with 10 µM TRAP-6 for 2 min in NSCLC patient samples (n = 128). Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. Statistical significance was calculated by two-tailed Mann–Whitney test. e CD62 expression change (ΔCD62P) in the different pPD-L1 quartile groups identified in unstimulated platelets of NSCLC patients (n = 128). Data are mean ± SEM. Statistical significance was calculated using Kruskal–Wallis test. f pPD-L1 expression change (ΔpPD-L1) in the different pPD-L1 quartile groups identified in unstimulated platelets of NSCLC patients (n = 128). Data are mean ± SEM. Statistical significance was calculated by Friedman and Dunn’s multiple comparisons test. g CD62P expression change (ΔCD62P, CD62P in stimulated platelets in % – CD62P in unstimulated platelets in %) after platelet activation with 10 µM TRAP-6 (n = 24), 2.5 µM ADP (n = 24), or 5 µg/ml collagen (n = 24). Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. h pPD-L1 expression change ΔpPD-L1 (pPD-L1 in stimulated platelets in % – pPD-L1 in unstimulated platelets in %) in NSCLC patients after platelet activation. Statistical significance was calculated by Kruskal–Wallis test. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. i Correlation between pPD-L1 expression in unstimulated platelets of 128 NSCLC patients and the ΔpPD-L1 upon platelet stimulation with 10 µM TRAP-6. Each dot represents a single patient. j Heatmap showing the calculated ΔpPD-L1 depending on the CD62P activation ranges (y-axis) and the quartiles of pPD-L1 level (x-axis) calculated in pooled data from 128 NSCLC patients. For details of subsampling and calculation used, see Methods and Supplementary Fig. 4. k Adjusted pPD-L1 levels in all 128 NSCLC patients upon calculated platelet pre-activation ranges (by CD62P expression level). a, i Correlation was determined by simple linear regression analysis. Source data are provided as a Source Data file.
Fig. 6 Platelets from NSCLC patients show increased PD-L1 protein levels upon activation. a Correlation between platelet-derived PD-L1 (pPD-L1) and platelet activation (CD62P expression) in 128 NSCLC patients. Each dot represents a single patient. b Platelets from a NSCLC patient assessed by transmission electron microscopy. PD-L1 stained with post-embedding immunogold-labeling. Upper and lower right, PD-L1 gold particles densely accumulate in α-granules. Scale bar left 1 µm, right 100 nm (n = 1). c, d Changes in CD62P (c) and the pPD-L1 (d) levels upon platelet stimulation with 10 µM TRAP-6 for 2 min in NSCLC patient samples (n = 128). Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. Statistical significance was calculated by two-tailed Mann–Whitney test. e CD62 expression change (ΔCD62P) in the different pPD-L1 quartile groups identified in unstimulated platelets of NSCLC patients (n = 128). Data are mean ± SEM. Statistical significance was calculated using Kruskal–Wallis test. f pPD-L1 expression change (ΔpPD-L1) in the different pPD-L1 quartile groups identified in unstimulated platelets of NSCLC patients (n = 128). Data are mean ± SEM. Statistical significance was calculated by Friedman and Dunn’s multiple comparisons test. g CD62P expression change (ΔCD62P, CD62P in stimulated platelets in % – CD62P in unstimulated platelets in %) after platelet activation with 10 µM TRAP-6 (n = 24), 2.5 µM ADP (n = 24), or 5 µg/ml collagen (n = 24). Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. h pPD-L1 expression change ΔpPD-L1 (pPD-L1 in stimulated platelets in % – pPD-L1 in unstimulated platelets in %) in NSCLC patients after platelet activation. Statistical significance was calculated by Kruskal–Wallis test. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. i Correlation between pPD-L1 expression in unstimulated platelets of 128 NSCLC patients and the ΔpPD-L1 upon platelet stimulation with 10 µM TRAP-6. Each dot represents a single patient. j Heatmap showing the calculated ΔpPD-L1 depending on the CD62P activation ranges (y-axis) and the quartiles of pPD-L1 level (x-axis) calculated in pooled data from 128 NSCLC patients. For details of subsampling and calculation used, see Methods and Supplementary Fig. 4. k Adjusted pPD-L1 levels in all 128 NSCLC patients upon calculated platelet pre-activation ranges (by CD62P expression level). a, i Correlation was determined by simple linear regression analysis. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Platelet-derived PD-L1 (pPD-L1) as prognostic and predictive marker in NSCLC. a Combined estimate of platelet CD62P (0–100%) and pPD-L1 levels predicts overall survival (OS) in 128 NSCLC patients; receiver-operating characteristics (ROC) analysis. b Kaplan–Meier analysis of overall survival (OS) dependent on the pPD-L1Adj as defined by quartile groups (very low (Q1), low (Q2), high (Q3) and very high (Q4)). Survival data refer to the time point of primary diagnosis (n = 128). c Overall survival (OS) in different pPD-L1Adj quartile groups according to the time point of platelet analysis (n = 128). b, c Statistical significance was calculated by log-rank test. d, e Association of pPD-L1Adj levels and different genetic alterations (KRAS (mut = 38, wt = 90), EGFR (mut = 19, wt =109), EML-4-ALK (alteration = 5, no alteration = 123) and ROS-1 (alteration = 6, no alteration 122)) (wt = wildtype, mut = mutation). Data are mean ± SEM. Statistical significance was calculated by two-tailed Mann–Whitney test. f–h pPD-L1Adj levels in patients with different tumor stage ((f), Tx = 8, T1 = 14, T2 = 23, T3 = 33, T4 = 50), lymph node invasion ((g), Nx = 9, N0 = 13, N1 = 11, N2 = 40, N3 = 55), and grade ((h), G1 = 19, G2 = 48, G3 = 61). Each dot represents a single patient. Statistical significance was calculated by Kruskal–Wallis test and Dunn’s multiple comparisons test. i Association of pPD-L1Adj levels with tumor origin (central = 42, peripheral = 79). j–l pPD-L1Adj is associated with the occurrence of metastasis (in general ((j), M0 = 25, M1 = 103) and at specific sites, including liver (confirmed = 31, no metastasis = 94) and brain (confirmed = 37, no metastasis = 91). f–l Each dot represents a single patient. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. Statistical significance was calculated by two-tailed Mann–Whitney test. m Kaplan–Meier curves estimates of PFS in patients with a pPD-L1Adj level > median (red) and pPD-L1Adj level < median (blue) treated with conventional chemotherapy (n = 62). n Kaplan–Meier curves estimates of PFS in patients with a pPD-L1Adj level > median (red) and pPD-L1Adj level < median (blue) treated with anti-PD-1 therapy (n = 20). o Kaplan–Meier curves estimates of PFS in patients with a TPS score > 1% (red) and TPS < 1% (blue) treated with anti-PD-1 therapy (n = 20). m–o Statistical significance was calculated by log-rank test. Source data are provided as a Source Data file.
Fig. 7 Platelet-derived PD-L1 (pPD-L1) as prognostic and predictive marker in NSCLC. a Combined estimate of platelet CD62P (0–100%) and pPD-L1 levels predicts overall survival (OS) in 128 NSCLC patients; receiver-operating characteristics (ROC) analysis. b Kaplan–Meier analysis of overall survival (OS) dependent on the pPD-L1Adj as defined by quartile groups (very low (Q1), low (Q2), high (Q3) and very high (Q4)). Survival data refer to the time point of primary diagnosis (n = 128). c Overall survival (OS) in different pPD-L1Adj quartile groups according to the time point of platelet analysis (n = 128). b, c Statistical significance was calculated by log-rank test. d, e Association of pPD-L1Adj levels and different genetic alterations (KRAS (mut = 38, wt = 90), EGFR (mut = 19, wt =109), EML-4-ALK (alteration = 5, no alteration = 123) and ROS-1 (alteration = 6, no alteration 122)) (wt = wildtype, mut = mutation). Data are mean ± SEM. Statistical significance was calculated by two-tailed Mann–Whitney test. f–h pPD-L1Adj levels in patients with different tumor stage ((f), Tx = 8, T1 = 14, T2 = 23, T3 = 33, T4 = 50), lymph node invasion ((g), Nx = 9, N0 = 13, N1 = 11, N2 = 40, N3 = 55), and grade ((h), G1 = 19, G2 = 48, G3 = 61). Each dot represents a single patient. Statistical significance was calculated by Kruskal–Wallis test and Dunn’s multiple comparisons test. i Association of pPD-L1Adj levels with tumor origin (central = 42, peripheral = 79). j–l pPD-L1Adj is associated with the occurrence of metastasis (in general ((j), M0 = 25, M1 = 103) and at specific sites, including liver (confirmed = 31, no metastasis = 94) and brain (confirmed = 37, no metastasis = 91). f–l Each dot represents a single patient. Boxes represent median and 25th to 75th percentiles, whiskers are minimum to maximum. Statistical significance was calculated by two-tailed Mann–Whitney test. m Kaplan–Meier curves estimates of PFS in patients with a pPD-L1Adj level > median (red) and pPD-L1Adj level < median (blue) treated with conventional chemotherapy (n = 62). n Kaplan–Meier curves estimates of PFS in patients with a pPD-L1Adj level > median (red) and pPD-L1Adj level < median (blue) treated with anti-PD-1 therapy (n = 20). o Kaplan–Meier curves estimates of PFS in patients with a TPS score > 1% (red) and TPS < 1% (blue) treated with anti-PD-1 therapy (n = 20). m–o Statistical significance was calculated by log-rank test. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 184

Metadata

Authors
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., Salih, H., Borst, O., Kopp, H.-G., & Zender, L.
Affiliations
  • Universitätsklinikum Tübingen (DE)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Tübingen (DE)
  • Robert Bosch Hospital (DE)
  • German Cancer Research Center (DE)
Corresponding author
Zender, Lars
Venue
Nature Communications
Published
2021-12-01
Volume
12
Issue
1
Pages
7005-7005
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3215972122
Cited by
175
References
54
Citations by year
2026: 26 · 2025: 45 · 2024: 43 · 2023: 44 · 2022: 17
FWCI
9.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Deutsche Forschungsgemeinschaft (EXC2180, Project B05, SFB-TR240, EXC 2180—390 900 677, SFB/TR-209, 314905040, 267467939, FOR-2314, TR240, 390900677)
  • Gottfried Wilhelm Leibniz Universität Hannover
  • Deutschen Konsortium für Translationale Krebsforschung
  • Leibniz-Gemeinschaft
  • National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, platelet-tumor cell interaction, FN1, alpha5beta1 integrin, GPIbα, tumor immune evasion, T cell suppression, platelet biomarkers
MeSH terms
Adult, Aged, Aged, 80 and over, Blood Platelets, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunologic Factors, Immunotherapy, Lung Neoplasms, Male, Middle Aged, T-Lymphocytes, Biomarkers, Tumor, Young Adult, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-021-27303-7
The paper
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., . . . Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-021-27303-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.